MP1032 Treatment in Patients With Moderate to Severe COVID-19

PHASE2CompletedINTERVENTIONAL
Enrollment

132

Participants

Timeline

Start Date

October 19, 2021

Primary Completion Date

July 28, 2022

Study Completion Date

September 5, 2022

Conditions
COVID-19
Interventions
DRUG

MP1032

Hard gelatin capsules for oral administration.

DRUG

Placebo

Placebo capsules matched to MP1032 for oral administration.

Trial Locations (31)

10310

Richmond University Medical Center, Staten Island

83404

Snake River Research PLLC, Idaho Falls

Unknown

MHAT Blagoevgrad AD, Blagoevgrad

MHAT Sv. Ivan Rilski Kozloduy, Kozloduy

MHAT Dr. Stamen Iliev AD, Montana

SHATPD Pernik EOOD, Pernik

MHAT Dr. Ivan Seliminski AD, Sliven

"UmhatemN.I.Pirogov", Sofia

SHATPPD Sata Zagora EOOD, Stara Zagora

Centre Hospitalier Victor Dupouy, Argenteuil

CHU de Grenoble Alpes, Grenoble

Centre Hospitalier Lyon Sud, Pierre-Bénite

DE KK Infektológiai Klinika, Debrecen

Flor Ferenc Hospital of Pest County, Kistarcsa

Ospedale GB Morgagni, Forlì

Ospedale SM Goretti, Latina

ASST-FBF-SACCO - Ospedale Luigi Sacco, Milan

IRCCS Ospedale San Raffaele, Milan

Policlinico di Napoli, Napoli

"Ospedale Santo Spirito! Pescara", Pescara

Policlinico Agostino Gemelli, Roma

"Spitalul Clinic de Boli Infectioase si Tropicale Dr. Victor Babes", Bucharest

Spitalul Municipal Caracal, Caracal

"Spitalul Clinic de Boli Infectioase Sfanta Parascheva", Iași

Clinica Anestezie si Terapie Intensiva, Timișoara

Hospital Clinic de Barcelona Hospital Clinic i Provincial, Barcelona

Hospital Ramon y Cajal, Edificio Central, Madrid

Hospital Clínico Universitario de Salamanca, Salamanca

Hospital Universitario Marqués de Valdecilla/IDIVAL, Santander

Hospital Universitario de Valme, Seville

Hospital Álvaro Cunqueiro, Vigo

Sponsors

Lead Sponsor

Collaborators (1)

All Listed Sponsors
collaborator

Syneos Health

OTHER

lead

MetrioPharm AG

INDUSTRY